Wolinsky, Jerry S.

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology

Multiple Sclerosis Research StudiesClinical Reasoning and Diagnostic Skills

Cited by 9,802

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology

Multiple Sclerosis Research StudiesClinical Reasoning and Diagnostic Skills

Cited by 6,969

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology

Multiple Sclerosis Research StudiesClinical Reasoning and Diagnostic Skills

Cited by 5,017

Defining the clinical course of multiple sclerosis: The 2013 revisions

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 3,177

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPsoriasis: Treatment and Pathogenesis

Cited by 2,021

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 1,905

Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis

Montalban, X., Arnold, D. L., Weber, M. S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E. C., Dangond, F., Syed, S., & Wolinsky, J. S. (2019) · New England Journal of Medicine

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 324

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

Fazekas, F., Barkhof, F., Filippi, M., Grossman, R. I., Li, D. K. B., McDonald, W. I., McFarland, H. F., Paty, D. W., Simon, J. H., Wolinsky, J. S., et al. (1999) · Neurology

Multiple Sclerosis Research StudiesAdvanced MRI Techniques and Applications

Cited by 287

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

Cohen, J. A., Reingold, S. C., Polman, C. H., & Wolinsky, J. S. (2012) · The Lancet Neurology

Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of Life

Cited by 233

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

Elliott, C., Wolinsky, J. S., Hauser, S. L., Kappos, L., Barkhof, F., Bernasconi, C., Wei, W., Belachew, S., & Arnold, D. L. (2019) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesAdvanced MRI Techniques and Applications

Cited by 217

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Wolinsky, J. S., Arnold, D. L., Brochet, B., Hartung, H.-P., Montalban, X., Naismith, R. T., Manfrini, M., Overell, J., Koendgen, H., Sauter, A., et al. (2020) · The Lancet Neurology

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 150

Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study

Gabr, R. E., Coronado, I., Robinson, M., Sujit, S. J., Datta, S., Sun, X., Allen, W. J., Lublin, F. D., Wolinsky, J. S., & Narayana, P. A. (2020) · Multiple Sclerosis Journal

Medical Image Segmentation TechniquesBrain Tumor Detection and Classification

Cited by 92

Multimodal quantitative magnetic resonance imaging of thalamic development and aging across the human lifespan: implications to neurodegeneration in multiple sclerosis

Hasan, K. M., Walimuni, I. S., Abid, H., Frye, R. E., Ewing-Cobbs, L., Wolinsky, J. S., & Narayana, P. A. (2011) · The Journal of Neuroscience

Multiple Sclerosis Research StudiesAdvanced Neuroimaging Techniques and Applications

Cited by 64

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life—A post hoc analysis of the TEMSO and TOWER studies

Mäurer, M., Comi, G., Freedman, M. S., Kappos, L., Olsson, T. P., Wolinsky, J. S., Miller, A. E., Dive-Pouletty, C., Bozzi, S., & O’Connor, P. W. (2016) · Multiple Sclerosis and Related Disorders

Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of Life

Cited by 39

Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Montalban, X., Piasecka-Stryczynska, K., Kuhle, J., Benkert, P., Arnold, D. L., Weber, M. S., Seitzinger, A., Guehring, H., Shaw, J., Tomic, D., et al. (2024) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 21